Medibank Pvt Ltd (ASX: MPL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medibank Pvt Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$10.19 billion
P/E Ratio
20.67
Dividend Yield
4.49%
Shares Outstanding
2.75 billion
Earnings per share
0.179
Dividend per share
0.17
Year To Date Return
8.60%
Earnings Yield
4.84%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medibank Pvt Ltd (ASX: MPL)
Latest News
52-Week Highs
Medibank share price hits 52-week high on US tech partnership
Opinions
Here's why I'll be watching the Medibank results like a hawk
Dividend Investing
Beyond ASX 200 bank shares: 3 insurance plays with nice dividends
Dividend Investing
I'd buy these two resilient ASX dividend shares for big income
Dividend Investing
Want a large and growing dividend? Medibank shares might be the answer
Dividend Investing
The 3 best ASX dividend shares for 2024
Opinions
Top ASX shares to buy in 2024 instead of investing in a term deposit
Healthcare Shares
Own Medibank shares? They just hit a new record high
Dividend Investing
Dividend investing: A proven path for Australian income seekers
Healthcare Shares
What is the outlook for Medibank shares in 2024?
Share Market News
Here are the top 10 ASX 200 shares today
Dividend Investing
Are Medibank shares a top buy for dividend income?
Frequently Asked Questions
-
Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.
-
Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 04 Sep 2024 | $0.0940 | 100.00% | Final | 26 Sep 2024 |
| 29 Feb 2024 | $0.0720 | 100.00% | Interim | 20 Mar 2024 |
| 13 Sep 2023 | $0.0830 | 100.00% | Final | 05 Oct 2023 |
| 02 Mar 2023 | $0.0630 | 100.00% | Interim | 22 Mar 2023 |
| 07 Sep 2022 | $0.0730 | 100.00% | Final | 29 Sep 2022 |
| 04 Mar 2022 | $0.0610 | 100.00% | Interim | 24 Mar 2022 |
| 08 Sep 2021 | $0.0690 | 100.00% | Final | 30 Sep 2021 |
| 03 Mar 2021 | $0.0580 | 100.00% | Interim | 25 Mar 2021 |
| 02 Sep 2020 | $0.0630 | 100.00% | Final | 24 Sep 2020 |
| 03 Mar 2020 | $0.0570 | 100.00% | Interim | 26 Mar 2020 |
| 04 Sep 2019 | $0.0740 | 100.00% | Final | 26 Sep 2019 |
| 05 Mar 2019 | $0.0570 | 100.00% | Interim | 28 Mar 2019 |
| 05 Sep 2018 | $0.0720 | 100.00% | Final | 27 Sep 2018 |
| 06 Mar 2018 | $0.0550 | 100.00% | Interim | 28 Mar 2018 |
| 06 Sep 2017 | $0.0000 | 100.00% | Final | 28 Sep 2017 |
| 07 Mar 2017 | $0.0525 | 100.00% | Interim | 29 Mar 2017 |
| 06 Sep 2016 | $0.0600 | 100.00% | Final | 28 Sep 2016 |
| 04 Mar 2016 | $0.0500 | 100.00% | Interim | 29 Mar 2016 |
MPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medibank Pvt Ltd
Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.
As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.
Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.
In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.
MPL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Nov 2024 | $3.70 | $-0.04 | -1.07% | 8,682,933 | $3.75 | $3.76 | $3.70 |
| 21 Nov 2024 | $3.74 | $0.01 | 0.27% | 4,100,877 | $3.77 | $3.78 | $3.72 |
| 20 Nov 2024 | $3.73 | $-0.07 | -1.84% | 8,030,387 | $3.79 | $3.80 | $3.72 |
| 19 Nov 2024 | $3.80 | $0.00 | 0.00% | 5,245,980 | $3.79 | $3.82 | $3.76 |
| 18 Nov 2024 | $3.80 | $-0.02 | -0.52% | 3,849,393 | $3.79 | $3.83 | $3.77 |
| 15 Nov 2024 | $3.82 | $0.08 | 2.14% | 7,203,722 | $3.75 | $3.82 | $3.74 |
| 14 Nov 2024 | $3.74 | $0.04 | 1.08% | 4,187,373 | $3.72 | $3.74 | $3.70 |
| 13 Nov 2024 | $3.70 | $-0.04 | -1.07% | 4,374,835 | $3.70 | $3.73 | $3.69 |
| 12 Nov 2024 | $3.74 | $0.05 | 1.36% | 5,489,947 | $3.71 | $3.75 | $3.69 |
| 11 Nov 2024 | $3.69 | $-0.03 | -0.81% | 7,895,170 | $3.72 | $3.73 | $3.69 |
| 08 Nov 2024 | $3.72 | $0.04 | 1.09% | 8,342,752 | $3.70 | $3.73 | $3.68 |
| 07 Nov 2024 | $3.68 | $0.03 | 0.82% | 5,127,142 | $3.68 | $3.70 | $3.65 |
| 06 Nov 2024 | $3.65 | $0.05 | 1.39% | 5,725,759 | $3.61 | $3.68 | $3.58 |
| 05 Nov 2024 | $3.60 | $-0.01 | -0.28% | 3,713,267 | $3.59 | $3.62 | $3.58 |
| 04 Nov 2024 | $3.61 | $0.06 | 1.69% | 6,524,403 | $3.61 | $3.63 | $3.56 |
| 01 Nov 2024 | $3.55 | $-0.04 | -1.11% | 4,361,787 | $3.57 | $3.58 | $3.53 |
| 31 Oct 2024 | $3.59 | $-0.01 | -0.28% | 5,584,887 | $3.60 | $3.61 | $3.55 |
| 30 Oct 2024 | $3.60 | $-0.04 | -1.10% | 5,309,643 | $3.63 | $3.64 | $3.59 |
| 29 Oct 2024 | $3.64 | $0.00 | 0.00% | 5,270,020 | $3.64 | $3.66 | $3.62 |
| 28 Oct 2024 | $3.64 | $-0.05 | -1.36% | 6,568,201 | $3.69 | $3.70 | $3.64 |
| 25 Oct 2024 | $3.69 | $0.01 | 0.27% | 3,366,313 | $3.68 | $3.71 | $3.68 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 02 Sep 2024 | David Koczkar | Expiry | 260,942 | $1,041,158 |
As advised by the company. Lapsed,1,839,835 Rights
|
| 02 Sep 2024 | David Koczkar | Buy | 457,907 | $1,827,048 |
Conversion of securities.
|
| 02 Sep 2024 | David Koczkar | Exercise | 457,907 | $1,827,048 |
Conversion of securities. 1,381,928 Rights
|
| 26 Aug 2024 | Jay Weatherill | Buy | 5,100 | $19,915 |
On-market trade.
|
| 26 Aug 2024 | Michael (Mike) Wilkins | Buy | 100,000 | $396,000 |
On-market trade.
|
| 26 Aug 2024 | Kathryn Fagg | Buy | 32,750 | $129,362 |
On-market trade.
|
| 26 Feb 2024 | Linda Nicholls | Buy | 5,400 | $19,710 |
On-market trade.
|
| 11 Dec 2023 | David Koczkar | Issued | 653,088 | $2,292,338 |
Issue of securities. 2,100,777 Performance Rights
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael (Mike) John Wilkins | Non-Executive DirectorNon-Executive Chairman | May 2017 |
Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He is a member of Investment and Capital and People Committee.
|
| Mrs Linda Bardo Nicholls | Non-Executive Director | Mar 2014 |
Mrs Nicholls has more than 30 years of experience as a senior executive and director in banking, insurance and funds management in Australia, New Zealand and the United States. She is the Chair of the Investment and Capital Committee and also a member of Risk Management Committee.
|
| Ms Kathryn Joy Fagg | Non-Executive Director | Mar 2022 |
Ms Fagg is a director and Chair with wide-ranging senior commercial and operational experience. She is a member of People Committee.
|
| Mr David Fagan | Non-Executive Director | Mar 2014 |
Mr Fagan has practised as a commercial lawyer for over 40 years. During that time, he held a variety of leadership positions at Clayton Utz culminating in the role of Chief Executive Partner for 9 years. He is the Chair of the Risk Management Committee.
|
| Mr David Koczkar | Chief Executive OfficerManaging Director | May 2021 |
Mr Koczkar has more than 25 years of strategy, innovation, commercial and operational experience across Australia, Asia and the UK, including previous work in the consulting and financial services industries.
|
| Mr Peter Dobie Everingham | Non-Executive Director | Mar 2022 |
Mr Everingham has over 25 years of corporate experience and is highly respected in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes key roles at companies with a strong consumer and technology focus. He is a member of People and Investment and Capital Committee.
|
| Dr Tracey Leigh Batten | Non-Executive Director | Aug 2017 |
Dr Batten has experience in the health services sector, with strong commercial, business and change leadership skills. She is the Chair of the People Committee and also a member of Risk Management Committee.
|
| Mr Gerard Dalbosco | Non-Executive Director | May 2021 |
Mr Dalbosco held a number of senior leadership roles including Oceania Managing Partner and CEO; Asia Pacific Joint Deputy CEO and Managing Partner-Markets; Oceania Managing Partner-Transaction Advisory Services; and Melbourne Managing Partner. Prior to these roles Gerard advised organisations across a range of sectors in respect of merger and acquisitions advice, valuations, and strategic, commercial and financial due diligence. He is a member of Risk Management Committee.
|
| Mr Jay Wilson Weatherill | Non-Executive Director | Mar 2024 |
Mr Weatherill has had a career in public office with expertise across a wide range of public policy areas including reform of social services. He is a member of Risk Management Committee.
|
| Ms Mei Ramsay | Group General CounselCompany Secretary | Mar 2011 |
-
|
| Mei Ramsay | Group General CounselCompany Secretary |
-
|
|
| Rob Read | Group Lead Amplar Health |
-
|
|
| Milosh Milisavljevic | Group Lead Chief Customer Officer |
-
|
|
| Mark Rogers | Group Lead Chief Financial Officer & Group Strategy |
-
|
|
| Tom Exton | Group Lead Chief Risk & Compliance Officer |
-
|
|
| Felicia Trewin | Group Lead Data & Technology |
-
|
|
| Rob Deeming | Group Lead Digital & Ventures |
-
|
|
| Kylie Bishop | Group Lead People Spaces & Sustainability |
-
|
|
| Meaghan Telford | Group Lead Policy Advocacy & Reputation |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 897,801,743 | 32.60% |
| J P Morgan Nominees Australia Pty Limited | 542,208,525 | 19.69% |
| Citicorp Nominees Pty Limited | 320,377,977 | 11.63% |
| National Nominees Limited | 81,375,680 | 2.95% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 71,271,047 | 2.59% |
| BNP Paribas Noms Pty Ltd | 46,314,124 | 1.68% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 21,450,620 | 0.78% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 20,002,248 | 0.73% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 8,980,884 | 0.33% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 7,590,106 | 0.28% |
| HSBC Custody Nominees (Australia) Limited i | 7,343,069 | 0.27% |
| Netwealth Investments Limited <Wrap Services A/C> | 6,630,695 | 0.24% |
| IOOF Investment Services Limited <Ips Superfund A/C> | 5,169,307 | 0.19% |
| UBS Nominees Pty Ltd | 4,975,089 | 0.18% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 4,961,790 | 0.18% |
| IOOF Investment Services Limited <Iisl Nal Isma 2 A/C> | 3,786,900 | 0.14% |
| Bond Street Custodians Limited <Cockej - F01832 A/C> | 3,784,143 | 0.14% |
| Ioof Investment Services Limited <Ioof Idps A/C> | 3,745,418 | 0.14% |
| Netwealth Investments Limited <Super Services A/C> | 3,279,571 | 0.12% |
| Solium Nominees (Australia) Pty Ltd <Vsa A/C> | 3,221,313 | 0.12% |
